"The two leading internal compounds are xB3 -001 and xB3 -007. xB3 -001 is a fusion protein containing Herceptin and is indicated for HER2+ cancer and HER2+ brain metastases while xB3 -007 is combined with Cerezyme and intended to treat neuropathic forms of Gaucher Disease, as well as GBA-associated Parkinson s Disease and Lewy Body Dementia. These two candidates are expected to enter the clinic in fiscal year 2022."

FY 2022 = Oct 1, 2021 to Sept 30, 2022.

Microsoft Word - BIOAF_SCIR.doc (q4cdn.com)

https://s1.q4cdn.com/460208960/files/News/2021/Zacks_SCR_Research_02092021_BIOAF_Vandermosten.pdf